Blood Advances

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	254
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	221
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	184
Addressing and overcoming disparities in GVHD	145
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	134
On a collision course: SARS-CoV-2 variants and CAR T cells	130
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	124
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	118
Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel	118
Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation	117
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses	113
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	106
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	104
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	97
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	96
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	92
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	88
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	88
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	86
Cortisol in sickle cell disease: a systematic review and meta-analysis	86
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv.	85
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv.	83
A Nested Case-Control Study of Monoclonal Gammopathy of Undetermined Significance in the Multiethnic Cohort Study.	79
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood	79
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	78

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	78
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	78
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	77
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	76
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	76
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	74
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	72
CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo	69
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel	69
CD58 loss in tumor cells confers functional impairment of CAR T cells	68
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	65
Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma	65
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1	65
Transfusion therapy for sickle cell disease: what’s new?	64
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	64
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	64
Best but not perfect: indirect measure of low iron stores	63
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	62
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	62
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	62
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	60
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation	59
Applying CRISPR-Cas9 screens to dissect hematological malignancies	58
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies	58
Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL	58
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	57
Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease	57
Bite-size introduction to canine hematologic malignancies	57
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma	57
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	56
Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria	56
Cystic Fibrosis and Sickle Cell Disease Associated with Non-administration of VTE Prophylaxis in Hospitalized Adults	56
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	56
Targeting bone marrow mesenchymal stromal cell–derived IL-6 to overcome acute myeloid leukemia chemoresistance	56
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	55
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	55
Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study	55
Steroid tapering after GVHD Rx: not too fast, not too slow	55
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction	54
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	54
Regional brain age is decreased in children with sickle cell anemia	53
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model	53
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel	52
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial	52
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	52
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	51
Complement C5 inhibition in early onset HELLP syndrome	51
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma	51
Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019	51
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	50

Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	50
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	50
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients	49
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	49
Long-term data needed for SCD gene therapy	48
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	48
Danazol treatment for telomere biology disorders: long-term results of a phase 1/2 study	48
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	48
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma	47
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma	47
ASH's commitment to SCD: building on 10 years of progress	47
Emerging from the shadows of congenital TTP	46
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study	46
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease	46
Interpretation of response in BOS: the definitions remain key	46
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay	45
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL	45
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia	44
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis	44
Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma	44
Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease	44
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma	44
AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease	44
Code status transitions in patients with high-risk acute myeloid leukemia	44
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy	43
Association between hemoglobin values and VWF assays: a multicenter investigation	43
Fanconi anemia neuroinflammatory syndrome: brain lesions and neurologic injury in Fanconi anemia	43
Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS	43
BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.	43
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities	43
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients	43
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia	43
Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia	42
The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease	42
Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia	42
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease	42
D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation	42
Myb drives B-cell neoplasms and myeloid malignancies in vivo	42
An αIIbβ3 ligand-mimetic murine monoclonal antibody that produces platelet activation by engaging the FcγIIa receptor	42
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv.	41
Hasselbalch HC, Kristiansen MH, Kjær L, et al. CHIP- JAK2V617F , chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidi	41
Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units	41
Dasatinib-induced spleen contraction leads to transient lymphocytosis	41
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?	41
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress	41
Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing	40
Anticoagulation, Recurrent Thrombosis and Major bleeding in antiphospholipid syndrome: UK multicentre observational study	40
Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts	40
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS	40
Platelet Rubicon drives thrombosis independent of autophagy	40
Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution	40
Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma	39
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes	39
Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq	39
Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti	39
Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis, and retrospective study	39
Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia	38
Growth and puberty in African children with sickle cell anemia treated with hydroxyurea	38
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia	38
PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome	38
High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera	38
Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma	38
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia	38
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial	38
Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis	38
Another step toward frontline BTK inhibitor therapy in MCL	37
Adaptation of Serious Illness Care Program to be delivered via telehealth for older patients with hematologic malignancy	37
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells	37
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities	37
Are CHOP-Plus Really CHOP-Minus Propositions in the Treatment of PTCL? A Comprehensive Assessment of the Strategy	37
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms	37
Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia	37
Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL	36
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study	36
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease	36
Impaired exercise capacity in post–COVID-19 syndrome: the role of VWF-ADAMTS13 axis	36
Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma	36
Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents	36
Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease	36
Long live the red blood cell: biotin tagging in SCD	36

Efficacy of radiotherapy and role of adjunctive immunochemotherapy in POEMS syndrome with solitary plasmacytoma	36
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial	36
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes	36
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling	36
Should we move to a genomic classification of neutrophilic myeloid neoplasms?	35
Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study	35
Commentary on the 2021 ASH Guidelines on use of anticoagulation in patients with COVID-19 being discharged from the hospital	35
Comments and concerns on the analysis of DAPS-ITP trial	35
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment	35
Bridging therapy before axi-cel for lymphoma	35
Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy	35
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?	35
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study	34
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease	34
Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease	34
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy	34
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML	34
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse	34
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma	34
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR	34
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH	34
Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period	34
Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodies	34
To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients	34
Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT	34
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial	34
Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia	33
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates	33
Gioacchino E, Koyunlar C, Zink J, et al. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Blood Adv. 202	33
Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis	33
A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML	33
Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom	33
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children’s Oncology Group report	33
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia	33
Deciphering the regulatory landscape of murine splenic response to anemic stress at single-cell resolution	33
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs	33
Hydroxyurea pharmacokinetics, it is a small world after all	33
World Coalition on SCD launches, sparking global focus on SCD diagnosis and care	32
Factor XI inhibitors: a new class of anticoagulants	32
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma	32
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia	32
Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism	32
Utilization patterns of hematology consultation in the intensive care unit: an 11-year single-center experience	32
Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?	32
Limitations of the epcoritamab vs odronextamab comparative analysis	32
Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells	31
Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination	31
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab	31
HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh	31
Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation	31
Circulating S100A8/A9 drives faster platelet COX-1 recovery via MRP4, impairing the duration of aspirin response	31
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study	31
Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS	31
Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia	31
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination	31
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma	31
Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis	31
Response to Qian et al	31
Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma	31
Exploring the role of C1-inhibitor in thrombotic diseases	31
HLA reduction of human T cells facilitates generation of immunologically multicompatible cellular products	31
T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy	31
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies	30
RNA-regulatory exosome complex suppresses an apoptotic program to confer erythroid progenitor cell survival in vivo	30
Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response	30
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912	30
Population-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder	30
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma	30
Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor	30
Prognostic impact of patient-reported symptoms in multiple myeloma	30
International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL	30
Synthetic lethality of decitabine plus ATR inhibition for TP53 -mutated AML	30
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population	30
The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals	30
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs	30
Efficacy and safety of dapsone in adult primary immune thrombocytopenia	30
Cellular and biochemical heterogeneity contributes to the phenotypic diversity of transfusion-dependent β-thalassemia	30
Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF	30
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms	30
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence	29
Age-associated hematopoietic variants in the rhesus macaque	29
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19–depleted pediatric haploidentical HCT for hematologic malignancy	29
Do sophisticated models give the full picture of allogeneic hematopoietic stem cell transplantation effect?	29
Pregnancy after hematopoietic stem cell transplant: an international multicenter study	29
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia	29
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma	29
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group	29
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD	29
Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination	29
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia	29
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy	29
KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease	29
Racial and socioeconomic status diversity and GVHD outcomes	29
Implementing ASH’s guidelines for acute medical care for incarcerated children and adults with sickle cell disease	29
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation	29